Canadian experts: peptide hype is outpacing the research
Published October 26, 2026. News from July 30, 2026, as reported by CP24, cited below. Opinions below belong to the people named.
Quick take: three Canadian academics told CP24 that peptide popularity has run ahead of the evidence, and Health Canada declined to comment on the US panel's vote.
Who said what
| Person | Reported view |
|---|---|
| Timothy Caulfield, University of Alberta | Called the FDA panel's decision "tremendously frustrating" and said there is no evidence for peptides as promoted by the wellness industry |
| Bob Hancock, University of British Columbia | Said there are many peptides but very few have actual benefits |
| David Sabatino, Carleton University | Worried that cosmetic use of prescription weight-loss drugs raises demand and cost for patients who need them |
What Health Canada said
A spokesperson said the agency could not comment on FDA decisions. Health Canada also pointed to its June court injunction against an online seller and its April advisory. Injectable peptides remain regulated as prescription drugs.
How to read this
These are expert opinions, not rulings. The FDA panel vote was advisory only. See the vote scorecard, the BPC-157 evidence gap and how to read peptide news.
Ready to order?
Paste it in the Promo code box in the order summary at checkout, then press Apply. Confirm the discount line before you pay.
Common questions
Who criticized the FDA panel vote?
Timothy Caulfield and Bob Hancock, per CP24.
Did Health Canada respond to the FDA vote?
A spokesperson said the agency could not comment on FDA decisions.
Is the FDA vote final?
No. It was an advisory recommendation.
Sources
- CP24: Peptides are rising in popularity but health experts warn very few have any benefits (Jul 30, 2026)
- AJMC: FDA panel backs 6 peptides for compounding (Jul 31, 2026)
Summarised in my own words. Read the originals for the full detail.